---
figid: PMC7341904__er.2019-00007f1
figlink: pmc/articles/PMC7341904/figure/fig1/
number: Figure 1
caption: Upregulation of the MAPK pathway in tumor cells leads to proliferation and
  progression of thyroid cancer. Increased signaling along the MAPK pathway is caused
  by genetic mutations occurring in the pathway (such as those of BRAF and RAS), activation
  of receptor tyrosine kinases due to mutations (such as those of RET), overactivation
  of these kinases by growth factors, and fusion receptor tyrosine kinases (such as
  RET and NTRK fusions). Shown are several drugs capable of targeting upstream receptor
  tyrosine kinases, specific mutations, and genetic rearrangements that are either
  FDA approved for thyroid cancer or of interest in treating this disease. Furthermore,
  constitutively activated MEK (due to BRAF V600E or RAS mutations) leads to decreased
  expression of thyroid-specific genes, particularly NIS, resulting in RAI refractoriness.
  Inhibition of BRAF or MEK reverses this effect and restores RAI avidity. Furthermore,
  complex interplay between the immune system and cancer cells exists, including inhibitory
  and stimulatory interactions. Expression of inhibitory ligands such as programmed
  death-ligand 1 (PD-L1) on tumor cells effectively turns off the T cells, leading
  to evasion of the immune response. Blockade of such signals with checkpoint inhibitor
  drugs is depicted in the figure. Several immunotherapeutic drugs are approved for
  several solid tumors but not thyroid cancer. CTLA-4, cytotoxic T-lymphocyte–associated
  protein 4; FGFR, fibroblast growth factor receptor; MHC, major histocompatibility
  complex; NIS, sodium iodide symporter; PD-1, programmed cell death protein 1; PI3K,
  phosphoinositide 3-kinase; TCR, T-cell receptor.
pmcid: PMC7341904
papertitle: 'Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.'
reftext: Maria E Cabanillas, et al. Endocr Rev. 2019 Dec;40(6):1573-1604.
pmc_ranked_result_index: '9085'
pathway_score: 0.902091
filename: er.2019-00007f1.jpg
figtitle: Upregulation of the MAPK pathway in tumor cells leads to proliferation and
  progression of thyroid cancer
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7341904__er.2019-00007f1.html
  '@type': Dataset
  description: Upregulation of the MAPK pathway in tumor cells leads to proliferation
    and progression of thyroid cancer. Increased signaling along the MAPK pathway
    is caused by genetic mutations occurring in the pathway (such as those of BRAF
    and RAS), activation of receptor tyrosine kinases due to mutations (such as those
    of RET), overactivation of these kinases by growth factors, and fusion receptor
    tyrosine kinases (such as RET and NTRK fusions). Shown are several drugs capable
    of targeting upstream receptor tyrosine kinases, specific mutations, and genetic
    rearrangements that are either FDA approved for thyroid cancer or of interest
    in treating this disease. Furthermore, constitutively activated MEK (due to BRAF
    V600E or RAS mutations) leads to decreased expression of thyroid-specific genes,
    particularly NIS, resulting in RAI refractoriness. Inhibition of BRAF or MEK reverses
    this effect and restores RAI avidity. Furthermore, complex interplay between the
    immune system and cancer cells exists, including inhibitory and stimulatory interactions.
    Expression of inhibitory ligands such as programmed death-ligand 1 (PD-L1) on
    tumor cells effectively turns off the T cells, leading to evasion of the immune
    response. Blockade of such signals with checkpoint inhibitor drugs is depicted
    in the figure. Several immunotherapeutic drugs are approved for several solid
    tumors but not thyroid cancer. CTLA-4, cytotoxic T-lymphocyte–associated protein
    4; FGFR, fibroblast growth factor receptor; MHC, major histocompatibility complex;
    NIS, sodium iodide symporter; PD-1, programmed cell death protein 1; PI3K, phosphoinositide
    3-kinase; TCR, T-cell receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGFR4
  - FGFRL1
  - FGFR1
  - FGFR3
  - FGFR2
  - PDGFRB
  - PDGFRA
  - FLT1
  - FLT4
  - KDR
  - RET
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - HRAS
  - KRAS
  - NRAS
  - TAS2R38
  - BRAF
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - NTRK1
  - NTRK2
  - NTRK3
  - AKT2
  - AKT3
  - AKT1
  - MAP2K1
  - MAP2K2
  - CD274
  - MTOR
  - MAPK3
  - MAPK1
  - TRA
  - TRB
  - TRD
  - TRG
  - CD28
  - SLC5A5
  - CTLA4
  - SSTR2
  - Sorafenib
  - Vandetinib
  - Cabozantinib
  - Axitinib
  - Pazopanib
  - Lenvatinib
  - Sunitinib
  - Dabrafenib
  - Vemurafenib
  - Encorafenib
  - Trametinib
  - Cobimetinib
  - Binimetinib
  - Selumetinib
  - Everolimus
  - Temsirolimus
  - Lu-DOTATATE
genes:
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: RET
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RET/PTC
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: RET/PTC
  symbol: PTC
  source: hgnc_prev_symbol
  hgnc_symbol: TAS2R38
  entrez: '5726'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK1
  entrez: '4914'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK2
  entrez: '4915'
- word: NTRK
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK3
  entrez: '4916'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PDL1
  symbol: PDL1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: NIS
  symbol: NIS
  source: hgnc_alias_symbol
  hgnc_symbol: SLC5A5
  entrez: '6528'
- word: NIS
  symbol: NIS
  source: hgnc_alias_symbol
  hgnc_symbol: SLC5A5
  entrez: '6528'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: SSTR2
  symbol: SSTR2
  source: hgnc_symbol
  hgnc_symbol: SSTR2
  entrez: '6752'
chemicals:
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Vandetinib
  source: ''
  identifier: ''
- word: Cabozantinib
  source: MESH
  identifier: C558660
- word: Axitinib
  source: MESH
  identifier: C503983
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Lenvatinib
  source: MESH
  identifier: C531958
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Encorafenib
  source: ''
  identifier: ''
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Binimetinib
  source: MESH
  identifier: C581313
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Lu-DOTATATE
  source: MESH
  identifier: C447941
diseases: []
---
